CORONA Remedies Ltd. (CORONA) Share Price Hits 52-Week High
- August 4, 2026
- Posted by: Harsh Piplani
- Category: News
CORONA Remedies Ltd. Share Price surged to Rs 2,200, marking a 4.5% rise and reaching a fresh 52-week high of Rs 2,261.4. The market cap stands at Rs 12,828.94 crore.
CORONA Remedies Ltd. Share Price has reached a significant milestone today, hitting a fresh 52-week high of Rs 2,261.4. The stock opened at Rs 2,135 and closed at Rs 2,200, reflecting a 4.5% increase from the previous close of Rs 2,105.3. This surge has propelled the company’s market capitalisation to Rs 12,828.94 crore, drawing attention from investors and analysts alike. The Healthcare sector, in which CORONA Remedies operates, has been a focal point for market participants, and this latest price action underscores the company’s strong position within the industry.
CORONA Remedies Ltd. Share Price Today: Price Action Analysis
| Metric | Value |
|---|---|
| Current Price | Rs 2,200 |
| Previous Close | Rs 2,105.3 |
| Today's Change | +Rs 94.7 (+4.5%) |
| Day Open | Rs 2,135 |
| Fresh 52-Week High | Rs 2,261.4 |
| Day Low | Rs 2,135 |
| Current Volume | 6,186 |
| Turnover | Rs 1.36 crore |
| Market Capitalisation | Rs 12,828.94 crore |
CORONA Remedies Ltd. (CORONA) traded at Rs 2,200. versus the previous close of Rs 2,105.3, a rise of 4.5%. The stock opened at Rs 2,135, reached Rs 2,261.4, touched Rs 2,135. Reported volume was 6,186.
Today, CORONA Remedies Ltd. Share Price opened at Rs 2,135 and reached a high of Rs 2,261.4, marking a fresh 52-week high. The stock closed at Rs 2,200, up by Rs 94.7 or 4.5% from the previous close of Rs 2,105.3. The day’s low was Rs 2,135, and the turnover was Rs 1.36 crore with a volume of 6,186 shares traded. This price action indicates strong investor interest and momentum, as the stock broke through its previous 52-week high.
CORONA Remedies Ltd. (CORONA) Fundamental Analysis
| Metric | Value |
|---|---|
| Market Capitalisation | Rs 12,828.94 crore |
| P/E Ratio | 39.39x |
| P/B Ratio | 7.98x |
| ROE | 28.21% |
| ROCE | 26.35% |
CORONA Remedies Ltd. was valued at a P/E ratio of 39.39x, a P/B ratio of 7.98x. These multiples provide valuation context, but they should not be labelled expensive or inexpensive without a comparable peer or sector benchmark.
Profitability and capital efficiency were represented by ROE of 28.21% and ROCE of 26.35%. ROE relates profit to shareholder equity, while ROCE measures returns generated on the capital employed in the business.
Sector and Industry Context
| Metric | Value |
|---|---|
| Sector | Healthcare |
| Benchmark Scope | same sector |
| Company P/E Ratio | 39.39x |
| Benchmark Median P/E | 20.89x |
| Benchmark Average P/E | 73.74x |
| Benchmark P/E Range | 0x to 3,364.06x |
| Company P/B Ratio | 7.98x |
| Benchmark Median P/B | 1.9x |
| Company ROE | 28.21% |
| Benchmark Median ROE | 10.92% |
| Company ROCE | 26.35% |
| Benchmark Median ROCE | 13.29% |
| Company Market Capitalisation | Rs 12,828.94 crore |
| Benchmark Median Market Cap | Rs 139.24 crore |
CORONA Remedies Ltd. (CORONA) is classified under sector: Healthcare.
CORONA Remedies Ltd. (CORONA) has a P/E ratio of 39.39x, which is above the benchmark median of 20.89x, a difference of +88.56%. P/E is a valuation multiple and is not, by itself, a buy or sell signal.
CORONA Remedies Ltd. (CORONA) has a ROE of 28.21%, which is above the benchmark median of 10.92%, a difference of +158.33%. CORONA Remedies Ltd. (CORONA) has a ROCE of 26.35%, which is above the benchmark median of 13.29%, a difference of +98.27%.
Track stocks reaching yearly peaks through the Univest 52-week-high screener. The peer table below provides the company-level comparison.
Peer Comparison
| Company | Symbol | Market Cap (Cr) | P/E | P/B | ROE (%) | ROCE (%) |
|---|---|---|---|---|---|---|
| Kwality Pharmaceuticals Ltd. | KPL | 2,683.28 | 39.39 | 7.98 | 28.21 | 26.35 |
| Beta Drugs Ltd. | BETA | 2,474.26 | 62.88 | 9.95 | 18.65 | 22.17 |
| Dr Agarwals Eye Hospital Ltd. | DRAGARWQ | 2,421.1 | 34.54 | 6.99 | -2.6 | 16.92 |
| Sai Parenteral's Ltd. | SAIPARENT | 2,416.82 | 171.93 | 3.18 | 13.9 | 12.97 |
| Hester Biosciences Ltd. | HESTERBIO | 2,111.45 | 15.25 | 4.57 | 16.17 | 14.12 |
CORONA Remedies Ltd. (CORONA) has a P/E ratio of 39.39x compared with the displayed peer median of 39.39x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of 28.21% compares with a peer median of 16.17% across the companies shown in the table. ROCE stood at 26.35% versus the displayed peer median of 16.92%, providing a capital-efficiency comparison. CORONA Remedies Ltd. (CORONA) has a market capitalisation of Rs 12,828.94 crore. Among the 5 peers shown, 0 have a larger market capitalisation.
Why Investors Are Watching CORONA Remedies Ltd.
- Fresh 52-week high at Rs 2,261.4, indicating strong price momentum.
- High P/E and P/B ratios compared to sector medians, reflecting premium valuation.
- Strong ROE and ROCE, showcasing superior profitability and efficiency.
- Significant market cap within the Healthcare sector, positioning as a major player.
About CORONA Remedies Ltd.
CORONA Remedies Ltd. operates in the Healthcare sector, focusing on pharmaceuticals and drugs. The company is known for its innovative approach and robust product portfolio, catering to various therapeutic segments. With a strong market presence and commitment to quality, CORONA Remedies has established itself as a key player in the industry, driving growth and delivering value to its stakeholders.
Track CORONA Remedies Ltd. Share Price on Univest
Use CORONA Remedies Ltd. (CORONA) live share-price page, Univest 52-week-high screener, Univest market blogs to review live stock data, yearly-high lists and related market analysis.
Investors can track the live share price of CORONA Remedies Ltd., along with technical indicators, fundamental ratios, shareholding patterns, 52-week levels, and market insights on Univest. Stay informed with the latest data and analysis to make well-informed investment decisions.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions
What is the current share price of CORONA Remedies Ltd.?
Ans. The current share price of CORONA Remedies Ltd. is Rs 2,200, reflecting a 4.5% increase from the previous close of Rs 2,105.3. The stock moved 4.5% during the session. The intraday range extended from Rs 2,135 to Rs 2,261.4.
What was the 52-week high for CORONA Remedies Ltd.?
Ans. The 52-week high for CORONA Remedies Ltd. was Rs 2,261.4, achieved on 04 August 2026. The stock moved 4.5% during the session. The intraday range extended from Rs 2,135 to Rs 2,261.4.
How does CORONA Remedies Ltd.'s P/E ratio compare to the sector?
Ans. CORONA Remedies Ltd.'s P/E ratio of 39.39 is higher than the sector median of 20.89, indicating a premium valuation. The company trades at a P/E ratio of 39.39x. Its P/B ratio is 7.98x.
What is the market capitalisation of CORONA Remedies Ltd.?
Ans. The market capitalisation of CORONA Remedies Ltd. is Rs 12,828.94 crore, positioning it as a major player in the Healthcare sector. The company operates in the Healthcare sector. Its P/E ratio is 39.39x.
How does CORONA Remedies Ltd.'s ROE compare to its peers?
Ans. CORONA Remedies Ltd.'s ROE of 28.21% is higher than many of its peers, showcasing superior profitability. ROE stands at 28.21%. ROCE stands at 26.35%. The relevant peer median ROE is 10.92%.
What is the P/B ratio of CORONA Remedies Ltd.?
Ans. The P/B ratio of CORONA Remedies Ltd. is 7.98, significantly above the sector median of 1.9. The company trades at a P/E ratio of 39.39x. Its P/B ratio is 7.98x.
How does CORONA Remedies Ltd.'s ROCE compare to the sector?
Ans. CORONA Remedies Ltd.'s ROCE of 26.35% is well above the sector median of 13.29%, indicating efficient capital use. ROE stands at 28.21%. ROCE stands at 26.35%. The relevant peer median ROE is 10.92%.
Who are some of CORONA Remedies Ltd.'s peers?
Ans. Some peers of CORONA Remedies Ltd. include Kwality Pharmaceuticals Ltd., Beta Drugs Ltd., and Dr Agarwals Eye Hospital Ltd. Comparable listed companies include Kwality Pharmaceuticals Ltd., Beta Drugs Ltd., Dr Agarwals Eye Hospital Ltd.
What factors contributed to the recent surge in CORONA Remedies Ltd. Share Price?
Ans. The recent surge in CORONA Remedies Ltd. Share Price can be attributed to strong investor interest and positive market sentiment towards the Healthcare sector. The company's robust fundamentals, including high ROE and ROCE, have also played a role in boosting.
How does CORONA Remedies Ltd. compare to its peers in terms of market capitalisation?
Ans. CORONA Remedies Ltd. has a market capitalisation of Rs 12,828.94 crore, making it one of the larger companies in the Healthcare sector compared to its peers. This positions the company as a significant player in the industry.
